• Candel Therapeutics flagged a peer-reviewed Lancet Oncology publication of pivotal Phase 3 results for CAN-2409 in localized prostate cancer.
• Results were previously disclosed in December 2024, with extended follow-up presented at the American Urological Association 2026 meeting.
• Trial outcome showed fewer disease recurrences when CAN-2409 was added to curative-intent radiotherapy versus radiotherapy alone.
• Safety profile remained broadly consistent with standard treatment, with no meaningful increase in clinically significant toxicity.
• Data are expected to underpin a planned biologics license application submission in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020805PRIMZONEFULLFEED9730031) on June 02, 2026, and is solely responsible for the information contained therein.